Spotlight On... India hopes for a clinical trial upswing; Pierre Fabre taps BioAscent for compound management; and much more...

India's Council of Medical Research is pushing for a renewed emphasis on clinical trials in the country, hoping to reverse a downturn spurred by tightened regulations and safety concerns. The group is requesting government reforms that might make studies faster and easier to get running, pointing out that the country's high rates of infectious disease could benefit from a boost in clinical research. More

> Pierre Fabre signed a deal with service provider BioAscent Discovery that tasks the company with managing its library of drug compounds. News

> Pfizer ($PFE) is reportedly nearing a deal with Russian drug manufacturer Polysan to produce its products in the country. Story

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.